Biogen Inc (BSP:BIIB34)
R$ 169.49 1.36 (0.81%) Market Cap: 149.37 Bil Enterprise Value: 178.06 Bil PE Ratio: 15.80 PB Ratio: 1.56 GF Score: 75/100

Biogen Inc at Stifel CNS Days (Virtual) Transcript

Mar 28, 2023 / 01:15PM GMT
Release Date Price: R$234.01
Paul Andrew Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst

Great. Good morning, everybody. I'm very excited, and it's appropriate that the first panel of our CNS conference this year is with Biogen's Head of Development, Priya Singhal. So thank you, Priya, very much, for joining me again this year. It was a great discussion last year, and now I have a whole page-and-a-half of questions written out. I'm hoping we can try to get to as much as possible. For everybody joining, you can always feel free to shoot me a note if there are any specific questions you want me to ask, there also should be a link in the webcast for you to type in any questions. But maybe we can start and have a fulsome discussion on Alzheimer's, Priya, and thank you, again.

Questions & Answers

Paul Andrew Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst

I think one interesting topical question is related to the lecanemab Ad

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot